ZNF362 (zinc finger protein 362) is a transcription factor containing zinc finger DNA-binding domains that localizes to the nucleus [GO Annotations]. It functions as a sequence-specific DNA-binding transcription factor regulating gene expression through RNA polymerase II-mediated transcription [GO Annotations]. Clinically, ZNF362 is notable primarily for its involvement in acute lymphoblastic leukemia (ALL) pathogenesis. ZNF362 rearrangements constitute an emerging molecular subtype in B-cell precursor ALL, classified among novel genetic entities in the 2022 WHO Classification 1. These rearrangements generate a characteristic gene expression signature associated with mixed B/myeloid immunophenotype leukemias 2. ZNF362 fusions appear functionally similar to canonical ZNF384 fusions, as cases with ZNF384r-signature without canonical ZNF384 rearrangements sometimes harbor ZNF362 fusion partners instead 2. Additionally, a ZNF362-TCF4 fusion was identified as a novel genetic aberration in pediatric ALL 3. Beyond hematologic malignancies, ZNF362 has been identified as a regulatory transcription factor in the miRNA-TF-mRNA co-regulatory network implicated in Duchenne muscular dystrophy pathogenesis 4. The gene's complete molecular functions and broader disease implications require further investigation.